Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study

Journal of Rheumatology

Volumn 39, Issue 10, 2012, Pages 1929-1933

  Sanmartí, Raimon ^a   Cabrera Villalba, Sonia ^a   Gómez Puerta, José A ^a   Ruiz Esquide, Virginia ^a   Hernández, M Victoria ^a   Salvador, Georgina ^b   Ramirez, Julio ^a   Viñas, Odette ^a   Cañete, Juan D ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Anticitrullinated peptide protein antibodies; Citrullinated; Palindromic rheumatism; Rheumatoid arthritis

Indexed keywords

ANTICITRULLINATED PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PALINDROMIC RHEUMATISM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS;

EID: 84867093517     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120568     Document Type: Article

References (16)

1. Hench P, Rosenberg E. Palindromic rheumatism. A new oft-recurring disease of joints (arthritis, periarthritis, para-arthritis) apparently producing no articular residues. Report of thirty-four cases. Arch Intern Med 1944;73:293-321.
2. Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Pract Res Clin Rheumatol 2004;18:647-61. (Pubitemid 39549817)
3. Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS, Ramos-Remus C, Russell AS, Suarez-Almazor ME. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. J Rheumatol 1999;26:540-5. (Pubitemid 29125568)
4. Guerne PA, Weisman MH. Palindromic rheumatism: Part of or apart from the spectrum of rheumatoid arthritis. Am J Med 1992;93:451-60.
5. Salvador G, Gomez A, Vinas O, Ercilla G, Canete JD, Munoz-Gomez J, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 2003;42:972-5. (Pubitemid 37220965)
6. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006;33:1240-2. (Pubitemid 44025133)
7. Tamai M, Kawakami A, Iwamoto N, Arima K, Aoyagi K, Eguchi K. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. Scand J Rheumatol 2010;39:287-91.
8. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al. Systematic review: Accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010;152:456-64; W155-66.
9. Guerne PA. From palindromic rheumatism in current arthritis. In: van de Putte L, Furst D, Williams H, Van Riel P. Therapy of systemic rheumatoid disorders. New York: Marcel Dekker Inc.; 1998:425-59.
10. Sanmarti R, Graell E, Perez ML, Ercilla G, Vinas O, Gomez-Puerta JA, et al. Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Res Ther 2009;11:R135.
11. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006; 45:478-80.
12. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: A systematic literature review. Rheumatology 2011;50:311-6.
13. Bregeon C, Dajon JL, Renier G, Jegoude-Mauco F, Galland F, Fallah N, et al. [Palindromic rheumatism. Immunologic survey and study of development in 43 cases]. Rev Rhum Mal Osteoartic 1986;53:441-9.
14. Canete JD, Arostegui JI, Queiro R, Gratacos J, Hernandez MV, Larrosa M, et al. An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. Arthritis Rheum 2007;56:2784-8. (Pubitemid 47237298)
15. Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: Longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009;36:1873-5.
16. Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol 2000;27:41-6. (Pubitemid 30058627)